||Registry of biomedical companies:
 [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 450 active entries
42505 10th Street West
Lancaster, CA 93534
United States of America, California
Toll free: (888) 266-9294
Phone: (661) 723-7723
Stock symbol: SLP
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company's offerings are in two general areas: simulation tools and tools to analyze and predict properties for chemical structures.
The company's gold standard GastroPlus™ software simulates time-dependent behavior of drug molecules in human or animal physiological models. The program is used to predict drug absorption in the intestinal tract and the concentration vs. time of drug in blood plasma and various body organs and tissues. GastroPlus handles intravenous, immediate release, and controlled release dosage forms. It also can predict pharmacodynamic response, plus the influence of active transport, efflux, and metabolism. The company's DDDPlus™ software simulates in vitro dissolution experiments that are run in large numbers by formulation scientists. Through this simulation, formulators can predict the likely effects of changing various formulation parameters, such as the particle size distribution for the drug, the amounts of various excipients, certain process variables, and several experimental parameters.
The company's powerful ClassPharmer™ software employs patented algorithms to classify (cluster) molecules into classes that are based on common substructures. Unlike other software that employs "fingerprints" (sets of common molecular features that are not necessarily connected to each other), ClassPharmer actually generates the largest common connected group of atoms and bonds between them that identifies a group. Such classes have been shown to correlate very well with the mechanism of action of the molecules in a class, as well as with many of their Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties.
The company's ADMET Predictor™ software predicts a large number of important ADMET properties of organic compounds from just their molecular structure: permeability (human jejunal and cell monolayer), solubility, lipophilicity, blood-brain barrier permeation, volume of distribution in human, blood plasma binding in human, and seven types of toxicity. Additional models are added on a continuing basis. ADMET Predictor also features an advanced computational filter for fast in silico screening of virtual libraries of drug candidates as well as a novel approach to visualization of molecular data in chemical space. The company's ADMET Modeler™ software automates the difficult and tedious process of making high quality predictive structure-to-property models from sets of experimental data. Although it can be used in a stand-alone mode, ADMET Modeler has been designed to work seamlessly with ADMET Predictor ".out" files of structural descriptors as its inputs, and to send the selected final model back to ADMET Predictor to be incorporated as an additional predicted property.
The Company has two other businesses, Words+, Inc. and FutureLab™, which are based on its proprietary software technologies.
Last update of this entry: November 11, 2009